Functional consequences for primary human alveolar macrophages following treatment with long, but not short, multiwalled carbon nanotubes by Sweeney, S et al.
© 2015 Sweeney et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.  
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
International Journal of Nanomedicine 2015:10 3115–3129
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
3115
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S77867
Functional consequences for primary human 
alveolar macrophages following treatment with 
long, but not short, multiwalled carbon nanotubes
sinbad sweeney
Davide grandolfo
Pakatip ruenraroengsak
Teresa D Tetley
lung cell Biology, section 
of Pharmacology and Toxicology, 
National heart and lung Institute, 
Imperial college london, london, UK
Purpose: Multiwalled carbon nanotubes (MWCNTs) are a potential human health hazard, 
primarily via inhalation. In the lung, alveolar macrophages (AMs) provide the first line of 
immune cellular defense against inhaled materials. We hypothesized that, 1 and 5 days after 
treating AMs with short (0.6 μm in length; MWCNT-0.6 μm) and long (20 μm in length; 
MWCNT-20 μm) MWCNTs for 24 hours, AMs would exhibit increased markers of adverse 
bioreactivity (cytokine release and reactive oxygen species generation) while also having a 
modified functional ability (phagocytosis and migration).
Methods: Primary human AMs were treated with short and long MWCNTs for 24 hours, 
1 and 5 days after which toxicity end points, including cell death, reactive oxygen species genera-
tion, and inflammatory mediator release, were measured. AM functional end points involving 
phagocytic ability and migratory capacity were also measured.
Results: AM viability was significantly decreased at 1 and 5 days after treatment with 
MWCNT-20 μm, while superoxide levels and inflammatory mediator release were significantly 
increased. At the same time, there was reduced phagocytosis and migratory capacity alongside 
increased expression of MARCO; this coincided with frustrated phagocytosis observed by 
scanning electron microscopy. In contrast, the adverse bioreactivity of the shorter MWCNT-
0.6 μm with AMs (and any resulting reduction in AM functional ability) was substantially less 
marked or absent altogether.
Conclusion: This study shows that after 24-hour treatment with long, but not short, MWCNTs, 
AM function is severely affected up to 5 days after the initial exposure. This has potentially 
significant pathophysiological consequences for individuals who may be intentionally (via 
therapeutic applications) or unintentionally exposed to these nanomaterials.
Keywords: nanotechnology, MWCNTs, alveolar macrophages, cytokines, phagocytosis, 
bioreactivity
Introduction
The nanotechnology sector has become an important and rapidly growing global industry, 
developing and producing a vast array of nanomaterials (materials with at least one 
external dimension ,100 nm, [ISO/TS: 27687:2008]). Engineered multiwalled carbon 
nanotubes (MWCNTs) are one such nanomaterial whose production capacity is estimated 
at several thousand tons yearly.1 MWCNTs offer high strength-to-weight ratios, tensile 
strength, conductivity, and thermal stability. Typically occurring with diameters in the low-
nanometer range and lengths in the high-micrometer range, MWCNTs are being applied 
in industries such as electronics, automobile, aerospace, and nanomedicine (eg, drug/gene 
delivery and scaffolds for tissue engineering).2 Products already incorporating MWCNTs 
include computer components, aircraft structural components, and sporting equipment 
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such as tennis rackets, golf clubs, bicycles, golf irons, and 
baseball bats. Human exposure to MWCNTs can vary consid-
erably, depending on the production method, application, and 
use.3 Inhalation of MWCNTs is a primary concern, not least 
because of lessons learned from exposure to long, thin, needle-
like, and biopersistent amphibole asbestos fibers leading to the 
development of pulmonary mesothelioma.4 The fiber structure–
activity paradigm is of particular concern, as described by 
Donaldson, as the structural characteristics of fibers that impart 
pathogenic activity are thinness (allowing for respirability), 
length (promoting retention), and biopersistence, resulting 
in increased toxicity, inflammation, and carcinogenicity.5 
Indeed, MWCNTs can also fall under the World Health 
Organization’s definition of a fiber, ie, a particle longer than 
5 μm, less than 3 μm in width, and having an aspect ratio 
of .3:1.6 It is generally accepted that nanosized particles have a 
high deposition rate in the alveolar region of the lung.7–9 As with 
other nanoparticles, aerodynamic diameter governs MWCNT 
deposition in the lung. However, for MWCNTs that may have 
lengths well into the micrometer range, their actual diameters 
have been proposed to determine their alveolar deposition,10 
where the longitudinal axis of the MWCNTs aligns with the 
airstream.
Alveolar macrophages (AMs) provide the first line 
of immune cellular defense by removing foreign matter 
(microbes, particles, etc) from the alveolar space. AMs 
identify and subsequently phagocytose foreign matter using 
pattern recognition receptors such as toll-like receptors 
(TLR4), scavenger receptors, and receptors of endogenous 
opsonins.11–14 AMs also have important functional roles 
in removal of endogenous cellular debris and degradation 
of pulmonary surfactant (lipids and proteins).15 AMs that 
become laden with phagocytosed material are thought to 
migrate out of the alveolar space for eventual clearance via 
the mucociliary escalator system and the lymphatic system, 
thus critically maintaining a sterile and particle-free alveolar 
unit. While AMs are efficient operators in foreign matter 
removal from the peripheral lung, exposure to excessive 
burden or complex particle morphology can compromise 
their efficacy or result in their injury and eventual death. For 
example, AMs can suffer from a phenomenon termed particle 
“overload”, which results in compromised phagocytic and 
migratory clearance, while the attempted clearance of long 
thin fibers (eg, amphibole asbestos) can induce “frustrated” 
phagocytosis in exposed AMs.16–18 Such events result in pro-
tracted AM release of inflammatory cytokines, chemokines, 
interferons, and other soluble mediators; further recruitment 
of immune effector cells; increased production/release of 
free radicals (eg, reactive oxygen species [ROS]); and pos-
sible damage to the delicate underlying alveolar epithelium. 
These events may be a precursor to known MWCNT-induced 
pathologies such as pulmonary fibrosis19 and granulomatous 
inflammation20 in rodents following inhalation.
Previous work in our laboratory showed that the length of 
MWCNTs is a critical determinant of their adverse bioreactiv-
ity with primary human AMs (in terms of proinflammatory 
mediator release and cell death); following an acute (24 hours) 
treatment, AMs displayed greatest reactivity toward long 
MWCNTs (~20 μm in length) than toward short MWCNTs 
(~0.6 μm in length).21 Such acute injury to AMs may result 
in a more prolonged proinflammatory bioactivation and may 
impede their short- and long-term functional and migratory 
abilities. Thus, in the present study we hypothesized that, 1 and 
5 days after treating AMs with long MWCNTs (with an acute 
24-hour exposure), AMs would exhibit increased markers of 
adverse bioreactivity (cell death, ROS generation, and inflam-
matory mediator release) while also having a modified ability 
to phagocytose bacteria and a modified migratory capacity.
Materials and methods
ethics statement
The human lung tissue used in this study was surplus tissue 
obtained following resection for lung carcinoma. Written 
informed consent was obtained for all samples, and the study 
was carried out with the approval of the Royal Brompton and 
Harefield Ethical Committee (Ref: 08/H0708/73).
aM cell model
Primary human AMs were isolated from human lung having 
grossly normal appearance obtained following resection for 
lung carcinoma, as described by Witherden and Tetley.22 
AMs were isolated from a minimum of five subjects per 
experiment. Briefly, lung tissue sections were perfused by 
injection of 0.15 M sterile sodium chloride saline solu-
tion until the draining lavage ran clear and the cell count 
was ,1×104 cells/mL. The saline perfusate was collected 
and centrifuged at 240× g for 10 minutes at 20°C. The 
cell pellet was resuspended in RPMI cell culture medium 
containing 1% penicillin/streptomycin/l-glutamine (PSG) 
and 1% fetal bovine serum (FBS) and seeded for respective 
experiments. After AM adherence during incubation at 37°C 
with 5% CO
2
 (~3 hours), the culture medium was removed 
and nonadherent cells (including contaminating blood) were 
removed by gentle phosphate-buffered saline (PBS) washing. 
For experiments, AM cultures were maintained in RPMI cell 
culture medium containing 1% PSG and FBS incubated at 
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37°C with 5% CO
2
. We have shown previously that .95% of 
these cells are CD68+,23 are phagocytic, and show macrophage 
morphology under scanning electron microscope (SEM).24
aM treatment with MWcNTs
The MWCNTs used in this study were purchased from 
Nanothinx, Rio Patras, Greece. We have previously char-
acterized and reported on the physicochemical properties 
of these materials, both in distilled water and in cell culture 
medium.21 Briefly, MWCNT-0.6 μm and MWCNT-20 μm 
(as labeled by the manufacturer) were determined to have 
median lengths of 1.1 μm (range, 0.23–9.7 μm) and 19.3 μm 
(range, 0.6–30.8 μm), respectively. Both MWCNT-0.6 μm 
and MWCNT-20 μm had comparable median diameters 
of 30.6 nm (range, 19.5–47.6 nm) and 27.8 nm (range, 
15.6–41.9 nm), respectively. Brunauer, Emmett, and Teller 
(BET) measurements indicated that MWCNT-0.6 μm and 
MWCNT-20 μm had surface areas of 255.24 and 204.8 
m2/g, respectively. Both MWCNT-0.6 μm and MWCNT-20 
μm also have comparable carbon purities (ie, the % atomic 
carbon) of 87% and 95%. As characterized by us previously, 
the remaining elemental % is predominantly oxygen while we 
also see trace amounts of calcium, chlorine, phosphorus, and 
sodium (likely residual from the raw materials or catalysts 
or both). While the metal catalysts for these MWCNTs were 
not disclosed by the manufacturer, our previous analysis sug-
gests that these are likely to be aluminum (accounting for 
0.6% and 0.3% of total atomic content for MWCNT-0.6 μm 
and MWCNT-20 μm, respectively) and iron (,0.1% for 
both of the MWCNT formats). The surface charge of both 
MWCNT-0.6 μm and MWCNT-20 μm was also comparable 
at -13.2 and -12 mV, respectively. Both MWCNT materials 
were assayed for endotoxin contamination, using a Pierce 
LAL Chromogenic Endotoxin Quantitation Kit (Thermo 
Scientific, Waltham, MA, USA) and both were below the 
0.1 EU/mL limit of detection. AMs were treated with 10 μg/mL 
(prepared in RPMI 1640 culture medium) of MWCNT-0.6 μm 
or MWCNT-20 μm for 24 hours. This dose of MWCNT 
was chosen as we previously found it had maximal biore-
activity (interleukin [IL]-6 and IL-8 release) with sufficient 
viability, in AMs following a 24-hour treatment (in a dose 
range of 0.1–50 μg/mL), which we believed would allow 
us to examine whether AMs could maintain their immune 
functionality (phagocytosis, cytokine release, migration, etc) 
following treatment with these nanomaterials.21 Furthermore, 
this dose is comparable to those used in published in vivo 
rodent studies on MWCNT inhalation. For example, Ryman-
Rasmussen et al25 exposed mice to 4 and 0.2 mg/kg CNTs 
(a calculated dose was based on a 10% estimated deposition 
fraction) in their study, where the estimated total AMs were 
0.95×105,26 the low dose of which compares favorably with 
this study, where we exposed 1×105 AMs to 10 μg MWCNT. 
At the end of a 24-hour treatment period, AMs were washed 
three times with PBS, fresh RPMI 1640 culture medium was 
added, and AMs were incubated for a further 1 or 5 days 
posttreatment.
scanning electron microscopy
AMs were seeded at 0.5×106 cells/well on glass coverslips in 
24-well culture plates. Following treatment with 10 μg/mL 
of MWCNT-0.6 μm or MWCNT-20 μm for 24 hours, AMs 
were fixed with 2% glutaraldehyde in 0.1 M cacodylate buffer 
for 30 minutes, followed by three rinses (5 minutes each) with 
0.1 M cacodylate buffer. The AMs were then dehydrated with 
ethanol and sealed onto a SEM stub with Araldite (Huntsman 
Advanced Materials, Duxford, UK). The samples were then 
sputter-coated with a thin film of gold and examined under 
SEM with a Hitachi s4000 (Hitachi, Tokyo, Japan).
cell viability
MTS is a tetrazolium compound, 3-(4,5-dimethylthiazol-2-yl)-5- 
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
that can be reduced by dehydrogenase enzymes within living 
cells demonstrating cellular metabolic activity and cell viabil-
ity. Such reduction in the presence of an electron coupling 
reagent, phenazine ethosulfate, results in the production of 
formazan product that is soluble in tissue culture medium, and 
the absorbance of this formazan product can be measured using 
a spectrophotometer. AMs were seeded on 96-well plates at a 
density of 100,000 cells/well in RPMI 1640 culture medium 
(containing 5% PSG) at 37°C with 5% CO
2
. One and 5 days 
after treatment with MWCNTs, AMs were rinsed with PBS 
and incubated with RPMI 1640 culture medium containing 
the MTS reagent according to the manufacture’s protocol 
for 1.5 hours (CellTiter 96® AQueous One Solution Assay, 
Promega, Madison, WI, USA). The absorbance of formazan 
product in the culture medium was then read using a spectro-
photometer at a wavelength of 490 nm. We have established 
that the MWCNTs used in this study do not interfere with the 
formation of formazan and therefore do not interfere with the 
MTS cell viability assay (data not shown).
reactive oxygen species generation
One and 5 days posttreatment with MWCNTs, intracellu-
lar AM ROS (key contributors to cellular oxidative stress) 
were detected by measuring the oxidation of fluorescent 
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dihydroethidium (DHE). DHE is readily permeable to cells 
and is oxidized by ROS, primarily superoxide, to yield 
ethidium. Ethidium subsequently binds to DNA, which 
produces a detectable red fluorescence. In the present study, 
ROS production was measured with the DHE probe using 
a variation of the protocol derived from Budd et al.27 AMs 
were seeded on 96-well plates (black, with a clear bottom) 
at a density of 100,000 cells/well in RPMI 1640 culture 
medium (containing 5% PSG) at 37°C with 5% CO
2
. One 
and 5 days posttreatment with MWCNTs, AMs were rinsed 
with PBS and incubated with RPMI 1640 culture medium 
containing 100 μL of 10 μM DHE (Invitrogen, Paisley, 
UK) in RPMI 1640 culture medium for 30 minutes. At the 
end of DHE incubation, AMs were washed twice to remove 
extracellular probe and read in a fluorescence plate reader 
at an excitation/emission (Ex/Em) of 485/595 nm. We 
assessed potential MWCNT interference in the DHE assay 
by adding the DHE probe to each of the MWCNT materials 
(10 μg/mL) in a cell-free setup. We did not observe any spon-
taneous ethidium production with detectable red fluorescence, 
and therefore concluded that the MWCNTs used in this study 
did not interfere with the DHE assay. In addition, the fluo-
rescence of treated and nontreated AMs was measured in the 
absence of the DHE probe, to allow any interference by AM 
autofluorescence to be removed from the measurement.
Measurement of inflammatory mediator 
release
One and 5 days posttreatment with MWCNTs, AM mediator-
conditioned culture medium was assayed for concentrations 
of the inflammatory cytokines (human IL-6, IL-1β, and 
tumor necrosis factor alpha [TNF-α]) and the inflammatory 
chemokine (human IL-8) using sandwich enzyme-linked 
immunosorbent assays (ELISA). The assays were performed 
using DuoSet® antibody kits and according to the manufactur-
er’s directions (R&D Systems Inc., Minneapolis, MN, USA). 
In the ELISA, we assessed potential MWCNT interference 
by spiking a 1,000 pg/mL standard solution of IL-6 or IL-8 
with increasing doses of both MWCNT materials (10 μg/mL). 
ELISA was performed on the standard alone and the MWCNT 
spiked standard. We did not observe any significant differences 
in the measured concentration of the nonspiked and MWCNT 
spiked standard, and therefore concluded that the MWCNTs 
used in this study did not interfere with the ELISA.
Phagocytosis of Escherichia coli
The phagocytic capacity of AMs, 1 and 5 days after 24-hour 
treatment with 10 μg/mL MWCNT-0.6 μm or MWCNT-20 μm, 
was determined by measuring the uptake of fluorescein-labeled 
Escherichia coli (E. coli), using a commercially available 
kit, according to the manufacturer’s instructions (Vybrant 
Phagocytosis Assay Kit, Molecular Probes, Paisley, UK). 
Briefly, AMs were seeded on 96-well plates (black, with 
a clear bottom) at a density of 100,000 cells/well in RPMI 
1640 culture medium (containing 5% PSG) at 37°C with 5% 
CO
2
. One and 5 days posttreatment with MWCNTs, AMs 
were rinsed with PBS and incubated with RPMI 1640 culture 
medium containing fluorescein-labeled E. coli for 3 hours. At 
the end of the incubation period, AMs were washed twice to 
remove extracellular, nonphagocytosed E. coli. Interfering 
fluorescence, from any residual extracellular nonphagocytosed 
E. coli, was quenched by addition of trypan blue according to 
the manufacturer’s instructions. AMs were then imaged using 
a fluorescent microscope and green fluorescence intensity was 
quantified using Simple PCI software (Hamamatsu, Shizuoka, 
Japan). The comparison between treated and nontreated AMs 
was made by quantifying total green fluorescence, which 
includes differences in both the number of AMs that contain bac-
teria and the amount of fluorescence per E-coli-positive AM.
Phagocytic receptor expression
The AM extracellular expression of the scavenger receptors 
(MARCO, MSR-1, and CD36) and TLR4, 1 and 5 days after 
24-hour treatment with MWCNT-0.6 μm or MWCNT-20 μm, 
was measured using flow cytometry. Briefly, treated and 
nontreated AMs were detached using nonenzymatic cell dis-
sociation solution (Sigma-Aldrich Co., St Louis, MO, USA) 
and washed in PBS. AMs were then incubated for 1 hour on 
ice with a mouse monoclonal antibody against human MARCO 
(Hycult Biotech, Uden, the Netherlands), human MSR-1 (R&D 
Systems), human CD36 (Hycult Biotech), and human TLR4 
(BioLegend, San Diego, CA, USA) or a mouse isotype control 
antibody (New England Biolabs, MA, USA). AMs were then 
washed twice with PBS and incubated with phycoerythrin-
labeled goat anti-mouse immunoglobulin G for 30 minutes on 
ice. AMs were again washed with PBS and resuspended for 
analysis in FACSFlow™ (Becton Dickinson and Company, 
NJ, USA) prior to analysis on a BD FACSCanto II™ flow 
cytometer (Becton Dickinson). A total of 10,000 gated events 
were measured for each sample.
Migratory capacity
The migratory capacity of AMs was determined by measuring 
their ability to migrate (via chemotaxis) toward zymosan- 
activated serum (Z-AS), 1 and 5 days after 24-hour treatment 
with MWCNT-0.6 μm or MWCNT-20 μm. Briefly, using 
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a protocol adapted from Warheit et al28 zymosan (Sigma-
Aldrich Ltd.) was prepared in sterile PBS and was added 
to FBS to yield a final concentration of 1 mg/mL; this was 
incubated in a shaking water bath at 37°C for 2 hours, fol-
lowed by 56°C for 30 minutes to cease complement activa-
tion. The Z-AS was centrifuged at 12,000× g for 15 minutes 
and the supernatants were removed and diluted to 10% in 
RPMI 1640 culture medium. 1×105 AMs, in 0.5 mL of RPMI 
1640 culture medium, were added to 8-μm-pore BD Fluo-
roBlok™ (Becton Dickinson) inserts. These inserts were then 
placed in a 24-well plate containing 1.5 mL RPMI 1640 culture 
medium. The AMs were then treated as before with 10 μg/mL 
of MWCNT-0.6 μm or MWCNT-20 μm for 24 hours. At the 
end of this treatment period, AMs were washed three times 
with PBS, fresh RPMI 1640 culture medium was added to the 
insert chamber and the lower chamber, and AMs were incu-
bated for a further 1 or 5 days posttreatment. After 1 or 5 days 
posttreatment, AMs were washed with PBS, fresh RPMI 
1640 culture medium with 1% FBS was added to the insert 
chamber, and the 10% Z-AS in RPMI 1640 culture medium 
was added to the lower chamber. The AMs were incubated 
at 37°C with 5% CO
2 
for 8 hours to allow migration to take 
place. AMs that migrated toward the Z-AS were stained 
with fluorescent calcein, imaged by fluorescent microscope 
fluorescence intensity, and quantified using the Simple PCI 
software. A chemokinesis control (placing RPMI 1640 
culture medium in both the insert and the lower chamber) 
was also performed. We were also wary of the possibility of 
MWCNTs physically obstructing the insert pores and falsely 
indicating reduced migration. To test for this phenomenon, 
we added 10 μg/mL of MWCNT-0.6 μm or MWCNT-20 
μm to the culture insert for 24 hours; 1.5 mL of PBS was 
added to the lower chamber. We then added dyed micro-
sphere 6.0 μm polystyrene Polybeads® (blue; Polysciences 
Inc., Eppelheim, Germany) to the insert (at 0.1% v/v), and 
the Polybeads® were left to pass through the pores, into the 
lower PBS-containing chamber, for 8 hours. The absorbance 
of the Polybeads® solution was measured at 450 nm, before 
and after passing through the insert, to determine if pore 
obstruction by MWCNT was a problem. We did not find any 
reduction in the concentration of Polybeads® before and after 
passage through the insert, thus MWCNTs did not obstruct 
the insert pores.
statistical analyses
Data from cell viability, ROS generation, IL-8 release, phago-
cytosis, phagocytosis receptor expression, and migratory 
capacity experiments are presented as the mean ± standard 
error, where five independent experiments were performed 
using five separate donor tissues for AM harvest. Significant 
differences between nontreated and MWCNT-treated AMs 
were determined using nonparametric Mann–Whitney test. 
In all analyses, a P-value ,0.05 was considered significant.
Results
scanning electron microscopy
AMs were treated with 10 μg/mL of MWCNT-0.6 μm 
or MWCNT-20 μm for 24 hours to assess respective cel-
lular morphological changes. Under SEM, untreated AMs 
appeared spherical with few filopodia and some membrane 
ruffling (Figure 1A). Following the 24-hour treatment with 
MWCNT-0.6 μm, AMs became activated and flattened 
out, exhibiting numerous filopodia (Figure 1B). Following 
the 24-hour treatment with MWCNT-20 μm, AM activa-
tion was also incited. However, recruitment of numerous 
AMs to sites of attempted phagocytosis was also observed 
(Figure 1C). Failure to completely engulf MWCNT-20 μm 
was found. Protruding MWCNTs were accompanied by 
membrane blebbing, severe membrane distortion, and 
multiple AM recruitment, suggesting MWCNT-induced 
frustrated phagocytosis (Figure 1D).
cell viability
AM viability, 1 and 5 days after the 24-hour treatment 
with 10 μg/mL MWCNT-0.6 μm or MWCNT-20 μm, was 
measured using the MTS assay (Figure 2). AM viability 
was not significantly changed at 1 or 5 days after treat-
ment with MWCNT-0.6 μm. In contrast, AM viability 
significantly decreased by 28% (P,0.05) and 51% 
(P,0.01) at 1 and 5 days, respectively, after treatment 
with MWCNT-20 μm.
reactive oxygen species generation
The fluorescent probe, DHE, was used to measure the genera-
tion of ROS (primarily, the superoxide anion) in AMs, 1 and 
5 days after 24-hour treatment with 10 μg/mL MWCNT-
0.6 μm or MWCNT-20 μm (Figure 3). AM superoxide levels 
were not significantly changed at 1 or 5 days after treatment 
with MWCNT-0.6 μm. Conversely, AM superoxide levels 
significantly increased 1.9-fold (P,0.05) and 1.7-fold 
(P,0.05) at 1 and 5 days, respectively, after treatment with 
MWCNT-20 μm.
Inflammatory mediator release
We observed that IL-6 release from AMs did not signifi-
cantly change at 1 or 5 days after the 24-hour treatment with 
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Figure 1 scanning electron micrographs showing incomplete phagocytosis of MWcNTs by alveolar macrophages.
Notes: (A) Nontreated AMs appeared spherical with few filopodia (white arrow) and some membrane ruffling (green arrow). (B) activation of aMs, with a large increase 
in numbers of filopodia (white arrows) upon exposure to MWCNT-0.6 μm. (C) Recruitment of AMs to a site where an AM has attempted to phagocytose MWCNT-20 μm, 
indicated with red arrows. Both exposures were for 24 hours, to 10 μg/mL of MWCNT-0.6 μm or MWCNT-20 μm. (D) Incomplete phagocytosis of MWCNT-20 μm by 
numerous aMs. The dashed rectangle highlights an area where a number of aMs have attempted and failed to completely engulf the MWcNTs while two more aMs have 
been recruited (red asterisks). The magnified region again shows protruding MWCNTs (red arrows) but also shows the AM undergoing membrane blebbing (gold arrows) 
and severe membrane distortion, indicative of cellular distress.
Abbreviations: MWcNTs, multiwalled carbon nanotubes; aMs, alveolar macrophages.
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Figure 2 Viability of aMs.
Notes: Viability of AMs, 1 and 5 days after a 24-hour treatment with MWCNT-
0.6 μm or MWCNT-20 μm, as determined by the MTs assay. cell viability data are 
presented as a percentage of the NT control (n=5) ± SEM; significant differences 
between nontreated and treated aMs are indicated, where *P,0.05 and **P,0.01.
Abbreviations: NT, nontreated; MWcNTs, multiwalled carbon nanotubes; aMs, 
alveolar macrophages; SEM, standard error of mean; MTS, 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
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Figure 3 aM reactive oxygen species generation.
Notes: ROS measured in AMs, 1 and 5 days after a 24-hour treatment with 
MWCNT-0.6 μm or MWCNT-20 μm, as determined by the fluorescent DHE probe 
assay (ex/em, 485/595 nm); n=5± SEM; significant differences between nontreated 
and treated aMs are indicated, where *P,0.05.
Abbreviations: NT, nontreated; MWcNTs, multiwalled carbon nanotubes; aMs, 
alveolar macrophages; rOs, reactive oxygen species; Dhe, dihydroethidium; ex/em, 
excitation/emission; seM, standard error of mean.
10 μg/mL MWCNT-0.6 μm (Figure 4A). IL-6 release by 
AMs significantly increased 3.3-fold (P,0.05) and 3.5-fold 
(P,0.05) at 1 and 5 days, respectively, after treatment with 
MWCNT-20 μm. We observed that IL-8 release from AMs 
did not significantly change at 1 or 5 days after the 24-hour 
treatment with 10 μg/mL MWCNT-0.6 μm (Figure 4B). IL-8 
release by AMs significantly increased 1.6-fold (P,0.05) 
1 day after treatment with MWCNT-20 μm; however, no 
significant changes were observed at the 5 days posttreatment 
time point. In addition, we did not observe any differences in 
the release of IL-1β or TNF-α following treatment of AMs 
with MWCNTs (data not shown).
Phagocytosis of E. coli
The phagocytic capacity of AMs, 1 or 5 days after the 24-hour 
treatment with 10 μg/mL MWCNT-0.6 μm or MWCNT-20 μm, 
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Figure 4 Inflammatory mediator release from AMs.
Notes: IL-6 (A) and IL-8 (B) release from AMs, 1 and 5 days after a 24-hour treatment with MWCNT-0.6 μm or MWCNT-20 μm. Mediator release is presented as pg/ml 
(n=5) ± SEM; significant differences between nontreated and treated AMs are indicated, where *P,0.05.
Abbreviations: NT, nontreated; MWcNTs, multiwalled carbon nanotubes; aMs, alveolar macrophages; seM, standard error of mean; Il, interleukin.
was determined by measuring the uptake of fluorescein-
labeled E. coli. We observed that AM phagocytic capacity 
was significantly reduced, by 15% (P,0.05), 1 day after 
the 24-hour treatment with 10 μg/mL MWCNT-0.6 μm 
(Figure 5); however, no significant changes were observed 
at the 5 days posttreatment time point. We observed that 
AM phagocytic capacity was significantly reduced, by 63% 
(P,0.01) and 85% (P,0.001), at 1 and 5 days, respectively, 
after treatment with 10 μg/mL MWCNT-20 μm.
Phagocytic receptor expression
The extracellular expression of the scavenger receptors 
(MARCO, MSR-1, and CD36) and TLR4, 1 and 5 days after 
the 24-hour treatment with MWCNT-0.6 μm or MWCNT-20 
μm, was measured using flow cytometry. We observed a 
slight, but nonsignificant, increase in TLR4 expression 1 day 
after the 24-hour treatment with 10 μg/mL MWCNT-0.6 μm 
(Figure 6); in contrast, MARCO, MSR-1, and CD36 were 
significantly increased, by 18%, 15%, and 14%, respectively 
(P,0.05), at the same time point. Five days after the 24-hour 
treatment with MWCNT-0.6 μm, there were no significant 
changes in the expression of any of the four receptors ana-
lyzed. At 1 and 5 days after treatment with MWCNT-20 
μm, MARCO expression was significantly increased 33% 
(P,0.05) and 23% (P,0.05), respectively; there were no 
significant changes for any of the other receptors at either 
time point.
Migratory capacity
The migratory capacity of AMs was determined by measur-
ing their ability to migrate toward zymosan-activated FBS, 1 
and 5 days after the 24-hour treatment with MWCNT-0.6 μm 
or MWCNT-20 μm. We observed that the migratory capacity 
of AMs did not significantly change at 1 or 5 days after the 
24-hour treatment with 10 μg/mL MWCNT-0.6 μm (Figure 7). 
At 1 and 5 days after treatment with MWCNT-20 μm, AM 
migratory capacity significantly decreased by 49% (P,0.05) 
and 76% (P,0.01), respectively.
Discussion
We have previously shown that MWCNT length is a criti-
cal determinant of their adverse bioreactivity with primary 
human AMs (in terms of proinflammatory mediator release 
and cell death); following a 24-hour treatment, AMs dis-
played great reactivity toward long MWCNTs (~20 μm 
in length) when compared to short MWCNTs (~0.6 μm in 
length).21 In the present study, we determined if there were 
functional adverse consequences for these AMs, 1 and 5 days 
after the exposure to the MWCNTs. These time points 
allowed us to assess the longer term significance of acute 
human AM exposure to MWCNT and how this may translate 
to real-life exposure scenarios.
Immediately following the 24-hour treatment with 
MWCNT-0.6 μm or MWCNT-20 μm, AMs were imaged 
under SEM to assess their interaction with the MWCNTs and 
any cellular morphological changes. We observed a failure of 
AMs to completely engulf MWCNT-20 μm (and associated 
protruding MWCNTs, accompanied by membrane blebbing 
and severe membrane distortion), strongly indicating that 
AMs are not comfortable dealing with such high aspect 
ratio materials. This is further evidenced by the absence of 
such responses with AMs exposed to the shorter MWCNT-
0.6 μm. Furthermore, 1 and 5 days posttreatment with 
MWCNT-20 μm, AM viability was significantly reduced, 
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Figure 5 aM phagocytic ability.
Notes: The ability of AMs to phagocytose fluorescein-labeled Escherichia coli, 1 and 5 days after a 24-hour treatment with MWCNT-0.6 μm or MWCNT-20 μm is shown. 
representative micrographs, of at least four independent experiments, show differential aM phagocytosis of E. coli (green) (A). The percentage change in aM phagocytosis, 
compared to the NT control aMs, is shown by a bar graph (B); n=5 ± SEM; significant differences are indicated, where *P,0.05, **P,0.01, and ***P,0.001.
Abbreviations: MWcNTs, multiwalled carbon nanotubes; aMs, alveolar macrophages; seM, standard error of mean; NT, nontreated.
while the viability of AMs treated with MWCNT-0.6 μm 
was unchanged at these time points.
Phagocytosis of particles has been shown to involve 
increased superoxide and associated increased superoxide 
anion release by AMs. Even though macrophages fail to 
internalize high aspect ratio fibers, there is still increased 
release of cellular superoxide,17 possibly due to membrane 
damage or loss of cellular integrity allowing release of the 
elevated intracellular superoxide anion. This could in turn 
lead to oxidative damage of neighboring AMs or alveolar 
epithelial cells. In the present study, we observed significantly 
increased intracellular AM superoxide levels, 1 and 5 days 
after treatment with MWCNT-20 μm but not MWCNT- 
0.6 μm. The inflammatory mediators IL-1β and TNF-α are 
putatively involved in the adverse bioreactivity of carbon 
nanotubes with macrophages.29,30 However, following treat-
ment of AMs with MWCNTs used in the present study, 
we did not observe any differences in the release of these 
mediators compared to the nontreated control AMs (data 
not shown). This may be due to the fact that we did not treat 
these AMs with priming agents, such as lipopolysaccharide, 
which in unpublished studies we have found to be necessary; 
thus the associated inflammasome pathway may not have 
been activated.
Previous research by us on the interactions between AM 
and MWCNT showed marked increases in IL-6 and IL-8 
release, following 24-hour treatment with MWCNT-20 μm 
and, to a lesser extent, MWCNT-0.6 μm.21 Importantly, in 
the present study, we observed that IL-6 release by AMs was 
still significantly increased, 1 and 5 days after treatment with 
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MWCNT-20 μm. IL-8 release by AMs was also significantly 
increased 1 day after treatment with MWCNT-20 μm; 
interestingly however, this increase had resolved at 5 days 
posttreatment time point. IL-6 is a pleiotropic cytokine asso-
ciated with the pathogenesis of numerous lung diseases such 
as asthma, chronic obstructive pulmonary disease (COPD), 
and idiopathic pulmonary fibrosis,31,32 while IL-8 is a potent 
chemoattractant for neutrophils and is generally associated 
with acute inflammation33 but which is also elevated in 
chronic inflammatory lung diseases, such as COPD, where 
the elevated circulating levels of IL-6 and IL-8 are proposed 
to be predominantly AM derived,34,35 therefore there are 
important pathological consequences for increases in these 
mediators from MWCNT-treated AMs.
A
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MWCNT-0.6 µm
MWCNT-20 µm
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Nontreated 
(chemotaxis control)
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Figure 7 (Continued)
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For those AMs that remained viable 1 and 5 days after the 
24-hour treatment with MWCNT-0.6 μm or MWCNT-20 μm, 
we were interested in determining their functional capabilities 
in terms of bacterial phagocytosis (important for maintain-
ing alveolar sterility) and migration (important for removal 
of phagocytosed material from the alveolar unit). Using 
fluorescein-labeled E. coli to measure phagocytosis, we 
discovered that there was no significant difference between 
phagocytosis by macrophages exposed to MWCNT-0.6 μm 
and untreated macrophages 5 days following exposure; 
the short MWCNTs inhibited phagocytosis at day 1 only 
by ~15%, indicating that treatment with the short MWCNT 
had no major, long-lasting effect on phagocytosis, correlating 
with the lack of induction of cell death by these MWCNT. 
In contrast, parallel studies of the effects of MWCNT-20 μm 
on macrophage phagocytosis resulted in markedly reduced 
phagocytosis compared to untreated control, which fell 
to only 27% and 15% that of untreated control cells on 
days 1 and 5, respectively. By comparison, the viability 
of these cells was 72% and 49% of control at these times, 
proportionally significantly higher than the phagocytic activ-
ity (Figure S1), indicating that the ability to phagocytose 
microbes was markedly inhibited by the long MWCNTs and 
the effect was chronic. The process of macrophage phagocy-
tosis is still in discovery.36 However, there are a number of 
extracellular receptors known to be important in initiating the 
process, including TLR4 and scavenger receptors.37
Consequently, we were interested to see if the marked, 
chronic reduction in AM phagocytic capacity in the pres-
ent study could be explained by differential expression of 
some of these extracellular receptors. There was a slight, 
nonsignificant, increase in TLR4 expression (important 
in recognition of lipopolysaccharide from Gram-negative 
bacteria) at 1 day following the 24-hour treatment with 
MWCNT-0.6 μm; however, in contrast, the scavenger recep-
tors MARCO, MSR-1, and CD36 (important in recognition 
of nonopsonized material) were all significantly increased at 
the same time point. Five days after treatment with MWCNT-
0.6 μm, there were no significant changes in the expression 
of any of the four receptors analyzed. In striking contrast, 
at 1 and 5 days after treatment with MWCNT-20 μm, 
MARCO expression was markedly increased while there 
were no significant changes for any of the other receptors at 
either time point. Given the significant reduction in E. coli 
phagocytosis, we expected to see a corresponding decrease 
in extracellular TLR4 expression; however, this was not 
the case. The upregulation of MARCO was particularly 
interesting, however, and this response may partly explain 
the decreased E. coli phagocytosis, as AMs may concentrate 
on phagocytosis of the long MWCNT rather than the bacte-
ria. MARCO has been shown to be a critical AM receptor 
for nonopsonized particles, in both rodent and human AM 
studies.38,39 Using J774.1 murine macrophages, Hirano et al40 
reported that MWCNTs (of unspecified length or function-
alization; 67 nm in diameter) may elicit cytotoxic effects 
by reacting with MARCO on the plasma membrane and 
rupturing the plasma membrane. Wang et al41 showed that 
apoptosis in RAW 264.7 murine macrophages, induced by 
MWCNTs (~0.5 μm in length, 10 nm diameter; acid-treated 
and taurine-functionalized), could be abated by pre-treating 
the cells with a scavenger receptor Class A (which includes 
MARCO) specific neutralizing antibody. In agreement with 
these studies, the marked and sustained (at day 5 postexpo-
sure) increase in MARCO expression for AMs treated with 
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Figure 7 aM migratory capacity.
Notes: Ability of AMs to migrate toward zymosan-activated fetal bovine serum, 1 and 5 days after a 24-hour treatment with MWCNT-0.6 μm or MWCNT-20 μm. 
Representative micrographs, of at least four independent experiments, showing differential AM migration (calcein-stained; green) (A). The percentage change in aM 
migration, compared to the NT control aMs, is shown by a bar graph (B); n=5± SEM; significant differences are indicated, where *P,0.05 and **P,0.01.
Abbreviations: NT, nontreated; MWcNTs, multiwalled carbon nanotubes; aMs, alveolar macrophages; seM, standard error of mean.
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MWCNT-20 μm in the present study indicates a key role for 
this receptor in AM–MWCNT interactions. An important 
study by Gao et al demonstrated that THP-1 macrophage 
recognition of MWCNTs can be changed by modification of 
their surface chemistry; the authors showed that increased 
binding of modified MWCNTs to scavenger receptors caused 
a reduction in MWCNT binding to mannose receptors, thus 
reducing inflammatory nuclear factor-κB activation and 
immunotoxicity in the THP-1 macrophages and in vivo in 
mice.42 Critically however, in the present study, we have 
shown that AMs that modify their receptor expression in 
favor of MARCO–MWCNT interactions may consequently 
have reduced microbial phagocytic capacity. Defective AM 
phagocytosis is seen in a number of chronic lung diseases 
(including COPD, asthma, and cystic fibrosis) and this 
potentially leads to increased bacterial colonization and 
increased frequency of bacterial-induced exacerbations of the 
diseases.14,43 The fact that we observed remarkably reduced 
E. coli phagocytosis, 5 days after extracellular MWCNT-20 μm 
were removed, indicates potential for development of similar 
pathological complications in individuals exposed to such 
materials.
This problem likely would be exacerbated by the persis-
tence of MWCNTs in the alveolar space, because of reduced 
clearance of long, high aspect ratio, MWCNT. It is generally 
accepted that AMs laden with phagocytosed material must 
migrate out of the alveolar space to begin eventual clear-
ance through proximal lymph nodes or via the mucociliary 
escalator.44 AMs have previously been shown to migrate 
toward complement component C5a.28,45,46 We therefore chose 
the zymosan-activated FBS (a rich source of C5a) method to 
measure migratory capacity. We observed that the migratory 
capacity of AMs did not significantly change at 1 or 5 days 
after the 24-hour treatment with MWCNT-0.6 μm; how-
ever, at 1 and 5 days after treatment with MWCNT-20 μm, 
AM migratory capacity was markedly decreased.
As outlined earlier in the observations of E. coli phago-
cytosis, any changes in migration should be considered in 
the context of the degree of cell death that occurred at the 
same time interval. Again, there was little effect of the short 
MWCNTs on macrophage migration. In contrast, exposure 
to long MWCNTs resulted in only 51% and 24% cell migra-
tion at days 1 and 5, in comparison to untreated control. This 
compares with 72% and 51% cell viability. Thus, the fall 
in cell migration is significantly more than the fall in cell 
death at the same time interval (Figure S1), indicating that, 
in addition to cell death, long MWCNTs cause a reduction 
in macrophage migration. Combined with the observed 
increased ROS generation and inflammatory mediator release 
and reduced microbial phagocytosis, the observed reduction 
in AM migratory capacity depicts an unfavorable situation 
for the alveolar unit and protection of its delicate epithelium. 
Such a high aspect ratio MWCNT exposure scenario could 
lead to cyclical episodes of attempted AM phagocytosis of 
the material, followed by AMs becoming stressed, their func-
tion being compromised, recruitment of more AMs, and an 
inability to migrate out of the alveolar space for clearance.
Conclusion
Our study reveals that treatment with long, but not short, 
MWCNTs can affect AM function. Our results clearly demon-
strate that 1 and 5 days after treating AMs with long MWCNTs 
for 24 hours, AMs continue to exhibit increased markers of 
adverse bioreactivity (cell death, ROS generation, and inflam-
matory mediator release), while they also have a reduced abil-
ity to phagocytose bacteria and a limited migratory capacity. 
This is in contrast to shorter MWCNTs, where these effects 
are substantially less marked or absent altogether. Given the 
complexity and diversity of MWCNT exposure scenarios, 
it is difficult to extrapolate the significance of the MWCNT 
concentration examined in this in vitro study. Nevertheless, 
these findings, using primary human AMs, have important 
implications for the design and application of MWCNTs, 
and future studies are needed to clearly elucidate the in vivo 
relevance of the differential interactions presented here.
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Figure S1 AMs treated with MWCNT-20 μm; viability, phagocytosis, and aM migration expressed as a percent of respective NT controls (100%).
Notes: t-Test comparison shows that the percent viability of treated AMs (yellow bars) was proportionally significantly higher than the percent phagocytic activity (blue 
bars) and percent migratory activity (red bars), indicating that the ability to phagocytose bacteria and to migrate were markedly inhibited by the long MWCNTs. Significant 
differences between percent viability and phagocytic activity or migratory activity are indicated, where *P,0.05.
Abbreviations: NT, nontreated; MWcNTs, multiwalled carbon nanotubes; aMs, alveolar macrophages.
